Immix Biopharma (NASDAQ:IMMX) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Immix Biopharma (NASDAQ:IMMX) from a hold rating to a sell rating in a report released on Sunday.

Several other analysts have also weighed in on IMMX. Mizuho started coverage on shares of Immix Biopharma in a research note on Monday, February 9th. They set an “outperform” rating and a $14.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, January 22nd. Finally, Citizens Jmp assumed coverage on Immix Biopharma in a research report on Monday, March 9th. They set an “outperform” rating and a $23.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Immix Biopharma currently has an average rating of “Hold” and an average target price of $15.00.

Immix Biopharma Stock Performance

Shares of IMMX stock opened at $10.00 on Friday. The stock has a market capitalization of $529.60 million, a price-to-earnings ratio of -12.99 and a beta of 0.25. Immix Biopharma has a one year low of $1.34 and a one year high of $10.71. The company’s 50-day simple moving average is $6.87 and its 200-day simple moving average is $4.78.

Institutional Investors Weigh In On Immix Biopharma

Institutional investors and hedge funds have recently modified their holdings of the stock. Velan Capital Investment Management LP purchased a new stake in shares of Immix Biopharma during the second quarter valued at $52,000. Vanguard Group Inc. boosted its holdings in shares of Immix Biopharma by 4.5% in the third quarter. Vanguard Group Inc. now owns 730,162 shares of the company’s stock worth $1,526,000 after buying an additional 31,625 shares during the period. Tocqueville Asset Management L.P. increased its position in shares of Immix Biopharma by 37.4% in the third quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock worth $84,000 after acquiring an additional 10,950 shares in the last quarter. Imprint Wealth LLC acquired a new position in Immix Biopharma in the 3rd quarter worth approximately $141,000. Finally, Citadel Advisors LLC purchased a new position in Immix Biopharma during the 3rd quarter worth approximately $188,000. 11.26% of the stock is owned by institutional investors and hedge funds.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.